

Laboratory Bulletin

Important News from DCL Medical Laboratories



March 16, 2009

DCL Medical Laboratories Introduces a Breakthrough Diagnostic Test: Reveal Cx™

DCL is excited to introduce the Reveal Cx™ Test to our clients. A proprietary diagnostic test in risk assessment for progression to cervical cancer, Reveal Cx™ is performed directly from the ThinPrep® Pap Test™ vial that is submitted for Pap testing. This Laboratory Bulletin contains important information regarding specimen collection and ordering for this test. If you have any questions, please contact DCL Client Services at (317) 874-1334 or toll free at (866) 874-1334.

Reveal Cx™

Patients with ASCUS/HPV+ or LSIL PAP results present challenges for appropriate case management. Because only approximately 30% of patients with a Pap diagnosis of ASCUS/HPV+ or LSIL will actually progress toward cervical cancer, additional diagnostic information may assist in improving case management. Reveal Cx™ provides the additional diagnostic information needed to better differentiate patients at risk for developing cervical cancer.

Reveal Cx™ is a fluorescence in-situ hybridization (FISH) probe test. The test is based on the specific detection of genetic amplification of chromosomal region 3q26. Amplifications of 3q26 have been correlated with increased progression to cancer.

Because patients with cervical cancer have demonstrated increased genetic amplification of the 3q26 region, this test can assist in the identification of those patients with increased risk of progression to advanced disease. Reveal Cx™ provides insight into which patients are at risk and helps in the development of more individualized patient care.

Ordering Reveal Cx™

Clients should use the "Request for Reveal Cx™ Testing" form to request Reveal Cx™ testing after having reviewed the patient's Pap and HPV results. The form should be faxed to DCL Client Services at (317) 874-1404. Please call Client Services at (317) 874-1334 or toll free at (866) 874-1334 to verify that your request was received.

All out-of-vial testing must be complete before the Reveal Cx™ test is requested. Reveal Cx™ testing will exhaust all of the sample in the vial and no residual specimen will be available for additional testing.

Reveal Cx™	
3Q	DCL #: 6012
Collection Container:	ThinPrep Vial
Storage/Stability:	30 days room temperature
Turnaround Time:	7 - 10 days after add-on request
Days Run:	M-F
Reference Range:	Negative
Clinical Utility:	<ul style="list-style-type: none">• Because patients with cervical cancer have demonstrated increased genetic amplification of the 3q26 region, this test can assist in the identification of patients with increased risk of progression to advanced disease and aids in the development of more individualized patient care.
Special Note:	Use the "Request for Reveal Cx™ Testing" form to request this test. The form should be faxed to DCL Client Services at (317) 874-1404.
CPT: 88367 x 2	Medicare Reimbursement: \$246.55 x 2